POSTN and neuroblastoma: To identify such MES cells potentially involved in minimal residual disease, one study recently proposed the use of a panel including PRRX1, POSTN, and FMO3 and documented their mRNA expression in peripheral blood, bone marrow, and peripheral blood stem cell samples of neuroblastoma patients using RT-qPCR [61].